2026 - 2027 Exhibitions
Kebo/Plastisud merge for mould and hot runner solutions
Swiss injection moulds firm Kebo will operate under the umbrella of the French Plastisud Group in the future, with the recent merger of the companies. Terms were not disclosed.
Founded in 1979, Kebo is a pioneer in the development of high-precision injection moulds and hot runner technology. With Gerold Keller and Daniel Bodenmann representing the second generation, the company has stood for the precision, quality, and customer focus for many years.
The merger with Plastisud is intended to enable more efficient use of capacities in order to better serve rising customer demand, particularly in the rapidly growing diabetes and obesity market. By combining the two companies, the strengths in the areas of innovation, technology, and rapid scalability are to be realised more effective for customers, the companies say.
Kebo will continue to operate as an independent company within the Plastisud Group. At the same time, the new majority owner is said to be committed to the Swiss location, which is to be further strengthened and expanded in a targeted manner.
Within the Plastisud Group, Kebo will cater to applications in the medical/pharmaceutical and laboratory industries.
Continuity is a key element of the transaction: the existing management team and the previous owners will remain on board to ensure a customer-focused transformation and collaboration.
For employees, customers, and suppliers, the merger will not change anything in day-to-day business.
“In Plastisud, we have found a partner for our family-owned company that shares our DNA and has the same high standards for quality and customer service. With this long-term succession plan, we are confident that Kebo will be able to further strengthen its strong position in the field of drug delivery devices,” says Gerold Keller, current co-owner of Kebo.
Plastisud also sees significant strategic potential in the transaction: “Kebo is an ideal fit for the Plastisud Group. This strategic alignment opens up very attractive opportunities for us in the medical and pharmaceutical sectors, a business that complements our existing product and customer portfolio very well,” says Laurent Buzzo, President/CEO of Plastisud.
With this merger, both owner-managed companies are laying the foundation for further growth, an even stronger market position, and the targeted expansion of their expertise and capacities in demanding and high-growth end markets.
Subscribe to Get the Latest Updates from IMA Please click here
©2026 Injection Moulding Asia. All rights reserved.